As digital pathology adoption grows, labs are no longer just evaluating scanners, image management systems, or LIS connectivity. Increasingly, they are asking a more strategic question, reflecting the vision that AI will unlock major efficiencies and growth opportunities in lab operations: what AI applications can this platform support, and how can I future proof my workflow decisions to ensure I’m ready to reap the benefits of AI down the line?
PathAI’s AISight® Image Management System was built with this in mind. Rather than taking a closed approach, it supports an open and interoperable model that allows laboratories to leverage the best AI applications developed industry wide - including those developed in-house by a lab - into a unified digital workflow.
In this blog, we look at how PathAI’s digital pathology platform supports AI Algorithm integration, what that experience looks like in practice, and why openness matters for labs making long-term digital pathology decisions.
Labs shouldn’t be evaluating digital pathology image management systems in isolation, as AI product availability - even if sequenced to a later date - may differ depending on the relationships and capabilities of the IMS.
Additionally, many labs already have established relationships with AI vendors, as well as specific clinical needs that shape their algorithm preferences, regulatory requirements tied to their region, and internal standards informed by validation studies and real-world experience. A digital pathology platform that forces them to give up those choices, or wait years for built-in alternatives, doesn’t actually increase flexibility - it simply replaces one set of constraints with another.
AISight Link was designed to address that gap. As the open API framework behind third-party algorithm integration within the AISight IMS Platform, it allows partner solutions to operate within the same workflow environment as PathAI’s own applications. This includes capabilities such as AI-generated overlays, Fields of Interest, quantitative result reporting, and case-level impression tools.
The result is a more efficient and unified user experience. Pathologists do not need to move between platforms or export files into separate viewers. Algorithm outputs can be surfaced directly within the same environment used for slide review and workflow management, helping reduce fragmentation and supporting a more streamlined digital workflow.
Figure 1: AISight Link Overview
PathAI has established integrations with seven third-party AI companies spanning multiple tumor types, modalities, and regulatory markets:
Deep Bio - Deep Bio’s DeepDx Prostate is a diagnostic aid designed to enhance precision in prostate cancer assessment. DeepBio also offers DeepDx, a breast cancer solution
Paige - Paige’s AI applications help alleviate time and resource pressures for pathologists across use cases including prostate, breast, colon, and pan-cancer.
Visiopharm - Visiopharm offers a full breast panel of applications, including ER, PR, Ki-67, metastasis detection, and HER2, as well as an application for non-small cell lung cancer (PD-L1).
Primaa - Primaa offers AI-powered diagnostic tools such as Cleo Breast and Cleo Skin designed to detect and quantify cancer biomarkers, lesion types, dimensions, margins, mitoses, and perineural invasion.
DoMore Diagnostics - DoMore Diagnostics’ Histotype Px® Colorectal is an outcome prediction biomarker for stage II and III colorectal adenocarcinoma, designed to inform decisions about whether to provide adjuvant chemotherapy following surgical resection.
Mindpeak - Mindpeak offers AI solutions for breast cancer biomarker analysis (HER2, ER/PR, Ki-67) and lung PD-L1, complemented by assays for prostate, gastric, esophageal, urothelial cancers, and onychomycosis in dermatopathology.
Stratipath - Stratipath offers the AI- based solution for prognostic risk profiling of breast cancer using routine histopathology slides.
These aren't banner partnerships - they are deep technical integrations, each requiring the partner's algorithms to pass PathAI's integration standards before becoming available to customers through the platform.
Figure 2 - A Growing Ecosystem of Third-Party AI Partner Solutions
The momentum is not just theoretical. One flagship academic medical center in the US, already using PathAI’s AIM-PD-L1 Suite and AIM-IHC Breast Panel across its pathology network, has expanded its use of PathAI’s AISight IMS Platform to deploy Deep Bio’s prostate algorithm at scale across multiple campuses. This offers a clear example of how laboratories are building multi-vendor AI strategies by standardizing on a single platform that provides access to a curated portfolio of both first-party and third-party tools, rather than managing fragmented point solutions.
A leading cancer center in South America, central to a national initiative to expand access to high-quality cancer diagnostics across a major public health system, is deploying AISight IMS Platform as its central digital pathology and AI hub. The deployment connects multiple regional labs and brings together PathAI’s ArtifactDetect, TumorDetect, and AIM-IHC Breast Panel algorithms alongside Paige’s prostate algorithm.
A third US health system is integrating an in-house prostate Gleason grading algorithm directly within the platform for use in its clinical workflows, demonstrating that the open architecture extends beyond commercial AI partnerships to support institution-built tools as well.
In practice, the ecosystem model looks like this: a lab uses PathAI’s TumorDetect and ArtifactDetect algorithms for quality control and case prioritization, AIM-IHC Breast Panel algorithms for biomarker quantification, and third-party tools for specific tumor types and indications - all within a single workflow, interface, and platform.
Choosing a digital pathology platform is a long-term decision. Most institutions enter into multi-year agreements, and the applications that matter today may not be the same ones needed several years from now. Labs need a platform that can adapt with the field, while preserving workflow continuity and room for future growth.
PathAI’s digital pathology platform was built with that reality in mind. Its architecture treats interoperability as a core platform capability, enabling labs to access PathAI applications alongside a broader ecosystem of validated third-party tools within a more unified workflow.
If you're evaluating digital pathology platforms and want to understand how PathAI’s platform handles algorithm integration, including which partner solutions are currently available, contact our team or request a demo to see it in action.
If you’re an AI pathology provider interested in integrating your solutions into PathAI’s AISight IMS platform, reach out to us at digitaldx@pathai.com.
Learn more about our AI solutions and third-party partner solutions here.
Regulatory status and intended use for third party algorithms may vary. Please refer to the applicable manufacturer documentation for current information regarding intended use, availability, and regulatory status.
All trademarks are the property of their respective owners.